Multitargeted Polyherbal Formulation for Diabetes-Associated Depression: Physicochemical Characterization and In-Vitro Safety Assessment

Keywords

Abstract

References

1. [1]1. Butalia, S., Kaplan, G. G., Khokhar, B., et al. (2016). Environmental risk factors and type 1 diabetes: Past, present, and future. Canadian Journal of Diabetes, 40(6), 586–593. https://doi.org/10.1016/j.jcjd.2016.05.002
2. [2]2. Katzmarzyk, P. T., Friedenreich, C., Shiroma, E. J., et al. (2022). Physical inactivity and non-communicable disease burden in low-income, middle-income, and high-income countries. British Journal of Sports Medicine, 56(2), 101–106. https://doi.org/10.1136/bjsports-2020-103640
3. [3]3. Williams, J. M., Poudel, B., & Shields, C. A. (2019). Sex differences in autoimmune type 1 diabetes. In Sex differences in cardiovascular physiology and pathophysiology (pp. 239–249). Academic Press. https://doi.org/10.1016/B978-0-12-813197-8.00015-4
4. [4]4. Roep, B. O., Thomaidou, S., van Tienhoven, R., et al. (2021). Type 1 diabetes mellitus as a disease of the β-cell: Do not blame the immune system? Nature Reviews Endocrinology, 17(3), 150–161. https://doi.org/10.1038/s41574-020-00443-4
5. [5]5. Kahn, C. R. (1994). Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes, 43(8), 1066–1084. https://doi.org/10.2337/diab.43.8.1066
6. [6]6. Robertson, R. P. (1995). Antagonist: Diabetes and insulin resistance—Philosophy, science, and the multiplier hypothesis. Journal of Laboratory and Clinical Medicine, 125(5), 560–564.
7. [7]7. Fujioka, K. (2007). Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. JAAPA, Suppl(12), 3–8. https://doi.org/10.1097/01720610-200712000-00001
8. [8]8. Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012). Type 2 diabetes mellitus: A review of current trends. Oman Medical Journal, 27(4), 269–273. https://doi.org/10.5001/omj.2012.68
9. [9]9. Eurich, D. T., McAlister, F. A., Blackburn, D. F., et al. (2007). Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: A systematic review. BMJ, 335(7618), 497. https://doi.org/10.1136/bmj.39314.620174.80
10. [10]10. Tilburt, J. C., & Kaptchuk, T. J. (2008). Herbal medicine research and global health: An ethical analysis. Bulletin of the World Health Organization, 86(8), 594–599. https://doi.org/10.2471/BLT.07.042820
11. [11]11. Gauttam, V. K., & Kalia, A. N. (2013). Development of polyherbal antidiabetic formulation encapsulated in the phospholipid vesicle system. Journal of Advanced Pharmaceutical Technology & Research, 4(2), 108–117. https://doi.org/10.4103/2231-4040.111527
12. [12]12. Chavda, B. P., & Sharma, A. (2017). Efficacy of combination of fenugreek, amla, and turmeric powder to reduce blood glucose level among diabetics: A literature review. International Journal of Nursing Care, 5(1), 55–59. https://doi.org/10.5958/2320-8651.2017.00012.6
13. [13]13. Indian Pharmacopoeia Commission. (1996). Indian pharmacopoeia (pp. 47–60). Government of India Press.
14. [14]14. Mukherjee, P. K. (2002). Quality control of herbal drugs. Business Horizons Pharmaceutical Publishers.
15. [15]15. Kokate, C. K., & Gokhale, S. B. (2007). Pharmacognosy (24th ed., pp. 112–114). Nirali Prakashan.
16. [16]16. Indian Pharmacopoeia Commission. (2007). Indian pharmacopoeia. Government of India.
17. [17]17. Khandelwal, K. R. (2008). Practical pharmacognosy. Pragati Books Pvt. Ltd.

Authors (5)